This interventional trial (n=500) designated as Ketamine Therapy Experiential Education Study (KTEES1), sponsored by Integrative Psychiatry Institute, investigates the effects of low-dose ketamine, administered intramuscularly to clinicians within a psychedelic-assisted therapy (PAT) training programme.
This study investigates a single sub‑anesthetic intramuscular ketamine experience (0.5–0.75 mg/kg, max 60 mg) offered to clinicians as part of an in‑person experiential PAT training weekend to assess changes in competencies for providing psychedelic-assisted and general therapy.
Primary outcomes are self‑reported measures of therapeutic efficacy and competency measured at baseline and four weeks post‑retreat; secondary outcomes include personality measures and magnitude of perceived mystical experiences, with comparisons between those who choose ketamine and those who do not.
Personal ketamine-assisted therapy experience delivered during an in-person training weekend.
Sub‑anesthetic 0.5–0.75 mg/kg IM; maximum 60 mg regardless of body weight.
Participants who opt out of or are contraindicated for ketamine; attend same training but do not receive ketamine.